- Home
- CRML vs PROK Comparison
CRML vs PROK Comparison
Compare CRML & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRML
- PROK
- Stock Information
- Founded
- CRML N/A
- PROK 2015
- Country
- CRML United States
- PROK United States
- Employees
- CRML N/A
- PROK N/A
- Industry
- CRML
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CRML
- PROK Health Care
- Exchange
- CRML NYSE
- PROK Nasdaq
- Market Cap
- CRML 146.8M
- PROK 126.8M
- IPO Year
- CRML N/A
- PROK N/A
- Fundamental
- Price
- CRML $2.49
- PROK $0.79
- Analyst Decision
- CRML
- PROK Buy
- Analyst Count
- CRML 0
- PROK 4
- Target Price
- CRML N/A
- PROK $5.00
- AVG Volume (30 Days)
- CRML 2.1M
- PROK 1.1M
- Earning Date
- CRML 02-01-2025
- PROK 05-09-2025
- Dividend Yield
- CRML N/A
- PROK N/A
- EPS Growth
- CRML N/A
- PROK N/A
- EPS
- CRML N/A
- PROK N/A
- Revenue
- CRML $476,979.00
- PROK $76,000.00
- Revenue This Year
- CRML N/A
- PROK N/A
- Revenue Next Year
- CRML N/A
- PROK N/A
- P/E Ratio
- CRML N/A
- PROK N/A
- Revenue Growth
- CRML 326.80
- PROK N/A
- 52 Week Low
- CRML $1.23
- PROK $0.46
- 52 Week High
- CRML $12.49
- PROK $4.44
- Technical
- Relative Strength Index (RSI)
- CRML 57.86
- PROK 45.47
- Support Level
- CRML $2.04
- PROK $0.65
- Resistance Level
- CRML $2.81
- PROK $1.18
- Average True Range (ATR)
- CRML 0.39
- PROK 0.17
- MACD
- CRML 0.20
- PROK 0.03
- Stochastic Oscillator
- CRML 79.70
- PROK 45.97
About CRML CRITICAL METALS CORPORATION
Critical Metals Corp is engaged in lithium exploration in Austria. It is focused on the development of its wholly-owned Wolfsberg Lithium Project (the Wolfsberg Project) located in Carinthia, Austria.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's own cells isolated from the patient intended for treatment. Its lead product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's own renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of development program for severe diabetic kidney disease.